Milani, Paolo
Paolo Milani researcher (ORCID 0000-0002-2268-9422)
VIAF ID: 43561958 (Personal)
Permalink: http://viaf.org/viaf/43561958
Preferred Forms
-
-
- 100 1 0 ‡a Milani, Paolo
-
- 100 1 _ ‡a Milani, Paolo
- 100 0 _ ‡a Paolo Milani ‡c researcher (ORCID 0000-0002-2268-9422)
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. | |
Attitudes about when and how to treat patients with AL amyloidosis: an international survey. | |
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. | |
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. | |
Enzo Zacchiroli, c1989: | |
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis | |
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. | |
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis. | |
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis | |
The lung in amyloidosis. | |
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms | |
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis | |
Monoclonal IgM-related AL amyloidosis | |
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma | |
Ein neues Verfahren, die Flügelschupfen der Schmetterlinge auf Papier zu übertragen. | |
The next generation of novel therapies for the management of relapsed multiple myeloma | |
Novel strategies for the diagnosis and treatment of cardiac amyloidosis. | |
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. | |
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. | |
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. | |
A practical approach to the diagnosis of systemic amyloidoses. | |
Presentation and outcome with second line treatment in AL amyloidosis previously sensitive to non-transplant therapies. | |
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis | |
Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells | |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide | |
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions | |
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response | |
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients | |
Treatment of AL amyloidosis with bendamustine: a study of 122 patients | |
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. | |
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis |